Abstract
Introduction/Background*Olaparib and niraparib are poly ADP-ribose polymerase inhibitors (PARPis) that have shown efficacy as maintenance treatment in platinum-sensitive relapsed ovarian cancer (PSROC). The aim of this study was to assess...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have